, FINAL DIAGNOSIS: PART 1: SENTINEL LYMPH NODE #1, RIGHT AXILLA, BIOPSY -METASTATIC CARCINOMA INVOLVING ONE LYMPH NODE (1/1) METASTATIC FOCUS MEASURES 3.0 CM IN GREATEST DIAMETER (ENTIRE LYMPH NODE). EXTRACAPSULAR EXTENSION IS IDENTIFIED MEASURING 0.2 X 0.1 CM. PART 2: BREAST, LEFT, SIMPLE MASTECTOMY -A. DUCTAL EPITHELIAL HYPERPLASIA PREDOMINANTLY ADIPOSE BREAST PARENCHYMA. SKIN AND NIPPLE HISTOLOGICALLY UNREMARKABLE. PART 3: BREAST, RIGHT, MODIFIED RADICAL MASTECTOMY -A. INVASIVE DUCTAL CARCINOMA 3.0 CM (GROSS) NOTTINGHAM GRADE 3 (COMBINED NOTTINGHAM SCORE 8/9: TUBULE FORMATION 3/3, NUCLEAR PLEOMORPHISM 2/3, MITOTIC ACTIVITY 3/3) WITH LYMPHOPLASMACYTIC INFILTRATE AND NECROSIS. B. DEFINITIVE LYMPHOVASCULART DUCTAL CARCINOMA IN SITU IS NOT LENTIFIED. RESECTION MARGINS FREE. DUCTAL EPITHELIAL HYPERPLASIA SKIN AND NIPPLE, HISTOLOGICALLY UNREMARKABLE.
TWENTY-TWO LYMPH NODES, NEGATIVE FOR METASTATIC CARCINOMA (0/22). G. PATHOLOGIC STAGE (see comment) H. RECEPTOR STATUS (see comment). CASE SYNOPSIS: SYNOPTIC - PRIMARY INVASIVE CARCINOMA OF BREAST LATERALITY: Right PROCEDURE: Modified radical mastectomy LOCATION: Upper inner quadrant SIZE OF TUMOR: Maximum dimension invasive component: 3.0 cm MULTICENTRICITY/MULTIFOCALITY OF INVASIVE FOCI: **TUMOR TYPE (invasive component):** 100-0-3 Ductal adenocarcinoma, NOS NOTTINGHAM SCORE: Nuclear grade: 2 carcinoma, infiltrating ductal, Nos 8500/3 Tubule formation: 3 Mitotic activity score: 3 Site: breest, NOS C50.9 3/13/11 he Total Nottingham score: 8 Nottingham grade (1, 2, 3): 3 ANGIOLYMPHATIC INVASION: Nο UUID:35FFF2A4-7956-47AC-8688-1AA6775E332B **DERMAL LYMPHATIC INVASION:** No TCGA-BH-A0DD-01A-PR CALCIFICATION: No SURGICAL MARGINS INVOLVED BY INVASIVE COMPONENT: PAGET'S DISEASE OF NIPPLE: LYMPH NODES POSITIVE: LYMPH NODES EXAMINED: METHOD(S) OF LYMPH NODE EXAMINATION: H/E stain SIZE OF NODAL METASTASES: Diameter of largest lymph node metastasis: 30.0 mm LYMPH NODE METASTASIS(-ES) WITH EXTRACAPSULAR EXTENSION: SKIN INVOLVED (ULCERATION): Nο T STAGE, PATHOLOGIC: p12 N STAGE, PATHOLOGIC: pN1a Criteria M STAGE, PATHOLOGIC: pMX Diagnosis Discrepancy Primary Tumor Site Discrepancy hitPAA Discrepancy Prior Malignancy History **ESTROGEN RECEPTORS:** positive PROGESTERONE RECEPTORS: positive HER2/NEU: Dual/Synchronous Prim Dual/Syricin
Case is (circle): DUAUFIED